Syndax Pharmaceuticals (FRA:1T3) General and Admin. Expense: €151.4 Mil (TTM As of Mar. 2026)


FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
25 GF Score
Price €19.03
! 7 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals General and Admin. Expense?

Syndax Pharmaceuticals FRA:1T3 +0.16% 25 General and Admin. Expense is €151.4 Mil as of Mar. 2026. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 7 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Syndax Pharmaceuticals's General and Admin. Expense for the three months ended in Mar. 2026 was €32.5 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €151.4 Mil.

Syndax Pharmaceuticals General and Admin. Expense Related Terms

Syndax Pharmaceuticals General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals General and Admin. Expense Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.34 31.40 0.00 115.44 153.45

Syndax Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.95 37.98 38.27 42.64 32.51
FRA:1T3
25GF Score
Syndax Pharmaceuticals Inc FRA:1T3
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €151.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €151.4 Mil mean?
Syndax Pharmaceuticals (FRA:1T3) has a General and Admin. Expense of €151.4 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Syndax Pharmaceuticals and its competitors.
Is Syndax Pharmaceuticals' General and Admin. Expense too high?
Syndax Pharmaceuticals' current General and Admin. Expense is €151.4 Mil. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' General and Admin. Expense compare to IOVA and GLUE?
Syndax Pharmaceuticals' General and Admin. Expense of €151.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current General and Admin. Expense is €151.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current General and Admin. Expense of €151.4 Mil. The current General and Admin. Expense is €151.4 Mil. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current General and Admin. Expense is €151.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score

Get the complete analysis for FRA:1T3

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.03
Price